ETF Holdings Breakdown of SAGE

Stock NameSage Therapeutic
TickerSAGE(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS78667J1088
LEI5493000JX4BJS9W6CN35

News associated with SAGE

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by MetLife Investment Management LLC
MetLife Investment Management LLC lessened its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 16.5% during the 4th quarter, Holdings Channel reports. The fund owned 25,636 shares of the biopharmaceutical company’s stock after selling 5,076 shares during the quarter. MetLife Investment Management LLC’s holdings in Sage Therapeutics were worth $139,000 at […] - 2025-05-09 08:20:57
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $8.81 Average PT from Brokerages
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been given a consensus rating of “Hold” by the nineteen ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and two have assigned a buy […] - 2025-03-31 06:04:58
US Bancorp DE Acquires 2,268 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)
US Bancorp DE raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 22.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,430 shares of the biopharmaceutical company’s stock after buying an additional 2,268 shares during the quarter. US […] - 2025-03-18 07:13:01
Sage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $6.99 and traded as high as $7.51. Sage Therapeutics shares last traded at $7.27, with a volume of 1,302,493 shares trading hands. Wall Street Analysts Forecast […] - 2025-03-11 07:46:51
Ieq Capital LLC Buys Shares of 10,468 Sage Therapeutics, Inc. (NASDAQ:SAGE)
Ieq Capital LLC purchased a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 10,468 shares of the biopharmaceutical company’s stock, valued at approximately $57,000. A number of other institutional investors also […] - 2025-03-03 08:50:56
Canaccord Genuity Group Issues Pessimistic Forecast for Sage Therapeutics (NASDAQ:SAGE) Stock Price
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its target price reduced by equities researchers at Canaccord Genuity Group from $9.00 to $8.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s target price would suggest a potential upside […] - 2025-02-14 08:40:45

SAGE institutional holdings

The following institutional investment holdings of SAGE have been identified

Date ETF ISIN/Name Num Shares Book value
2025-02-27 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 41,064USD 295,250 0.3%
2025-02-27 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 6,566USD 47,210 0.3%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 68,511USD 459,709 -1.6%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 28,973USD 194,409
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 28,973USD 194,409 -1.6%
2024-11-12 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 145USD 831
Total =174,232 USD 1,191,818
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.